Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	258-260
Number of pages	3
Journal	Journal of Clinical Epidemiology
Volume	142
DOIs	https://doi.org/10.1016/j.jclinepi.2021.10.026
Publication status	Published - Feb 2022

Access to Document

@article{72d9fb278f3a40e093ba4a798e0dc188,

title = "Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent",

author = "Leufkens, \{Hubert G.\}",

year = "2022",

month = feb,

doi = "10.1016/j.jclinepi.2021.10.026",

language = "English",

volume = "142",

pages = "258--260",

journal = "Journal of Clinical Epidemiology",

issn = "0895-4356",

publisher = "Elsevier",

}

TY - JOUR

T1 - Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent

AU - Leufkens, Hubert G.

PY - 2022/2

Y1 - 2022/2

UR - https://www.scopus.com/pages/publications/85123840211

U2 - 10.1016/j.jclinepi.2021.10.026

DO - 10.1016/j.jclinepi.2021.10.026

M3 - Comment/Letter to the editor

C2 - 34748906

AN - SCOPUS:85123840211

SN - 0895-4356

VL - 142

SP - 258

EP - 260

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

ER -